MG MED Inc. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
255
208
615
480
2,178
Depreciation, Depletion & Amortization
251
277
317
337
521
Other Funds
502
495
281
193
624
Funds from Operations
497
980
1,214
51
2,281
Changes in Working Capital
456
200
2,056
1,554
145
Net Operating Cash Flow
41
780
842
1,503
2,136
Capital Expenditures
3,314
323
254
481
1,983
Sale of Fixed Assets & Businesses
-
-
5
5
61
Purchase/Sale of Investments
45
11
10,000
100
2,612
Net Investing Cash Flow
3,269
312
11,515
260
1,654
Issuance/Reduction of Debt, Net
-
-
-
-
30,000
Net Financing Cash Flow
9
-
13,732
8,020
30,532
Net Change in Cash
3,236
468
1,375
6,257
26,742
Free Cash Flow
3,130
464
1,080
1,984
4,084
Other Sources
-
-
-
116
717
Change in Capital Stock
9
-
13,732
8,020
532
Exchange Rate Effect
-
-
-
-
-
Other Uses
-
-
1,265
-
3,061

About MG MED

View Profile
Address
Unit 1003, Elysia Building
Seoul SL 08511
Korea, Republic Of
Employees -
Website http://www.cancerrop.com
Updated 09/14/2018
Cancer Rop Co., Ltd. engages in the development of molecular diagnostic products. It operates through Molecular Diagnostics and Bio-Reagents Business divisions. The molecular diagnostic business division provides deoxyribonucleic acid (DNA) chips and polymerase chain reaction(PCR) kits.